The risk of skin cancer in renal transplant recipients in Queensland, Australia
The risk of skin cancer in renal transplant recipients in Queensland, Australia
复制标题
DOI：
10.1097/00007890-199603150-00008
复制
发表时间：
1996-03-15
期刊：
影响因子：
6.2
通讯作者：
Hardie, IR
中科院分区：
文献类型：
--
作者：
Bavinck, JNB;Hardie, DR;Hardie, IR
对澳大利亚昆士兰州1098例肾移植受者进行了长期回顾性随访研究，评估了免疫抑制治疗对皮肤癌发生风险的影响。或环孢菌素和硫唑嘌呤的组合，有或没有泼尼松龙。皮肤癌的累积发病率，通过寿命表分析计算，从免疫抑制1年后的7%逐渐增加到11年后的45%和70%。一个亚组的多变量分析比较了长期使用环孢素或硫唑嘌呤的患者发生皮肤癌的风险（每种药物加或不加泼尼松龙）和联合应用环孢素和硫唑嘌呤（加或不加泼尼松龙）的患者在两组之间没有差异。我们的结论是，与免疫抑制相关的皮肤癌风险增加可能与所使用的药物无关，而是免疫抑制本身的结果。
A long-term retrospective follow-up study was performed to evaluate the risk of skin cancer in 1098 renal transplant recipients in Queensland, Australia, In a subgroup, we also assessed the influence of immunosuppressive therapy on the risk of developing skin cancer: cyclosporine alone or in combination with prednisolone; azathioprine alone or in combination with prednisolone; or the combination of cyclosporine and azathioprine with or without prednisolone.The cumulative incidence of developing skin cancer, calculated by life table analysis, increased progressively from 7% after 1 year of immunosuppression to 45% after 11 years and to 70% after 20 years of immunosuppression.Multivariate analysis in a subgroup comparing the risk of developing skin cancer in patients on either long-term cyclosporine or azathioprine (each with or without prednisolone) and in patients on the combination of cyclosporine and azathioprine (with or without prednisolone) showed no differences between the groups. We conclude that it is likely that the increased risk of skin cancer associated with immunosuppression is independent of the agent(s) used and is a result of the immunosuppression per se.